Phenacetin was implicated as a causative factor in Alzheimer's disease (AD) in 1971. Although the chief metabolite, paracetamol, was earlier identified as responsible for its analgesic and antipyretic properties, a link with senile plaque formation does not appear to have been previously suspected. In common with paracetamol, so-called recreational drugs (RDs) likewise stimulate free radical activity, and might therefore pose a similar danger in terms of causing AD later in life. The case for regarding the brain as an even more delicate and vulnerable structure than currently believed, at risk especially from substances untested in man but of proven neurotoxicity in rodents and nonhuman primates, needs to be taken more seriously than at present.
INTRODUCTION
In 1986, anxiety was expressed that the prevalence of AD was expected to rise by between 9% and 77% in six developed countries between 1980 and 2000 as a consequence of demographic change (1). In the USA, incidence is anticipated to become more common as the population ages; for example, only two years ago, AD was projected almost to quadruple over the coming half-century (2) .
However, rises in prevalence due simply to ageing of the population may mask contributions from factors as yet unidentified (1) . A comparison between identical ethnic groups in the developed USA and in Nigeria has revealed relatively high and low incidences of AD respectively (3). The difference in the incidence of AD between the two communities suggests the existence of at least one widespread underlying cause which is more common in developed countries, is independent of the ageing process, and which still awaits identification (1, 4) . Meanwhile, the aim of significantly delaying the progress of cognitive decline by novel pharmacological means remains elusive (2) .
PHENACETIN AND ALZHEIMER'S DISEASE
The consumption of phenacetin and other analgesics began to rise steeply after World War II (5) . Excessive use of phenacetin has been linked with the development of AD (6) . At post mortem, senile plaques were found in six individuals with analgesic nephropathy, the ages of whom ranged from 52 to 67 years; total individual ingestion of phenacetin over the lifetimes of the subjects ranged from 10 to 25 kg. The frontal, temporal and occipital regions of the brain were affected, plaques being most obvious in the hippocampal gyrus. In contrast, no plaques were seen in two subjects aged 68 and 72 years from the series. The latter consumed 15 and 10 kg of aspirin respectively, but no phenacetin (6).
CONVERSION OF PHENACETIN TO PARACETAMOL
In man, the 4-ethoxy group rapidly splits off the phenacetin molecule, leaving paracetamol as the major metabolite (7). Paracetamol is mainly responsible for the analgesic and antipyretic actions of phenacetin (7); in the wake of these discoveries, use of the former as an inexpensive painkiller in tablets containing up to 500 mg became common practice. When taken regularly at dose levels of 4 g daily, a patient will ingest 1.47 kg paracetamol annually, theoretically equivalent to 1.73 kg phenacetin.
The possible relevance of paracetamol to the development of AD has not escaped attention entirely. In an assessment (8) of paracetamol, aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs), no significant association between risk of AD and duration of paracetamol usage was established. However, no distinction was made between chronic and occasional use, and information on the amounts ingested by each subject was not provided. In consequence, heavy users as a group escaped attention. The relative risk of developing AD from taking paracetamol for more than 2 years, although not statistically significant, was still 1.58. In contrast, NSAIDs lowered the relative risk significantly to 0.46 when the period of usage exceeded 2 years (8). When paracetamol is taken in conjunction with alcohol, the acute effects in terms of enhanced hepatotoxicity can be fatal (9) . The possibility that the injurious actions of paracetamol on the brain might be augmented by alcohol in surviving patients ought not to be discounted.
FREE RADICALS IN ALZHEIMER'S DISEASE
Evidence to suggest that AD is an outcome of increased free radical activity and oxidative stress in the brain continues to accumulate (10) . In view of its hepatoxicity, studies of the action of paracetamol in the body have focussed on the liver. Its chief metabolite is the highly reactive intermediate N-acetyl-4-benzoquinone imine (11) . Evidence from the whole body points to a stimulation of lipid peroxidation by paracetamol; the effect is markedly enhanced by food deprivation (12) . In addition, the drug impoverishes glutathione levels (11, 12) . The analgesic action of paracetamol confirms an effect either of the compound itself or of its metabolites on the brain; the production of cumulative forms of brain injury in tiny imperceptible steps can therefore not be ruled out entirely. Meanwhile, the sharp rise in prevalence of AD with increasing age (1) might be consistent with more frequent use of paracetamol for relief from augmenting pain as subjects grow older, or with a greater sensitivity of the elderly to its injurious effects, or perhaps with both.
BRAIN INJURY FROM RECREATIONAL DRUGS
The long-term consequences of most RDs have yet to be fully characterized. Users of RDs such as 3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy') have not reached the age at which AD might be expected, but a disturbing confluence of observations already gives more than sufficient cause for concern. Warnings that extensive usage may lead to altered neuronal structure (13) , producing slow and insidious neurotoxic actions (14) , were given some years ago. At a functional level, adverse effects of amphetamines on mental exercise (15, 16) and memory (16, 17) have been recently described; the extents of impairment were similar in both previous and current users (15) . Decreases in serotonin transporter binding correlated with the extent of MDMA use in man (18) ; similarly, decreased serotonin binding (19) and degeneration of serotonin presynapses have been observed in animals (20) . Evidence from studies in mice suggests that decreases in serotonin binding induced by methamphetamine ('Speed'; 'Ice') are caused by superoxide (21) .
FREE RADICALS AND NEUROLOGICAL DAMAGE
A litmus test for neuroleptic substances capable of inflicting subtle forms of injury on the brain may be the properties of increasing free radical flux and of compromising the generation of chemical energy (20) . This end may be achieved in a variety of ways; for example, either by increasing free radical production directly (19, 21, 22) , by decreasing the activities of scavenging enzymes (19, 22) , or, more simply, by substrate depletion (20) . MDMA causes long-term neurological degeneration in nonhuman primates at doses comparable with those used for recreational purposes (14, 16) . The uncritical willingness of some young people to set their mental abilities at risk by indulging in the use of RDs inadequately tested in man but known to cause irreversible neurological damage at comparable dose levels in animals and in nonhuman primates beggars belief. In years to come, forms of cumulative brain damage from RDs may make a further and wholly unexpected contribution of disastrous magnitude to the drug problem.
